Find Clinical Trial

A prospective, controlled, double blind, international study to assess the effects of strontium ranelate vs. placebo on the reduction of periprosthetic bone loss in patients with total hip arthroplasty The “Periprosthetic bone loss” study – The “Periprosthetic bone loss” study


← Back
Study Phase

Phase 3

Therapeutic Area

Rheumatology

IndicationOsteoporosis
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

STRONTIUM RANELATE,
S012911

Active Substance CodeS012911
Protocol CodeCL3-12911-037
EudraCT Code2010-020215-36
ISRCTN CodeISRCTN15928978


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility